SciSparc Ltd. (NASDAQ: SPRC) announced that its collaboration with Clearmind Medicine Inc. yielded positive safety profile results from its joint pre-clinical trial, which tested the proprietary combination of SciSparc’s CannAmide(TM) with Clearmind’s psychedelic molecule, MEAI, for alcohol consumption. Shares almost doubled at the open on Tuesday, as it nearly hit $4, and yielded wild price swings since, but this morning SciSparc announced that it will issue 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit), in an at-the-market priced transaction.
SciSparc is making a low volume move in premarket, at $3.19, up $0.32 (+11.15%) on 24,314 shares.
Concert Pharmaceuticals Inc (NASDAQ: CNCE), a clinical stage biopharmaceutical company that’s developing small molecule drugs, has made several wave moves since we first covered it, hitting a new 52 week high of $6.80 on 5,410,143 shares Friday.
The Lexington, Massachusetts based pharmaceutical company recently reported positive topline results for First CTP-543 Phase 3 clinical trial in Alopecia Areata and the highlights included; THRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses, Statistically Significant Hair Regrowth Observed as Early as Eight Weeks, CTP-543 Has Potential to be Best-in-Class for the Treatment of Alopecia Areata, and Topline Data from Second Phase 3 Trial, THRIVE-AA2, Expected Third Quarter of 2022
Even though it closed 92 cents off of its Friday high, Concert Pharmaceuticals is trading at $6.14, $0.26 (+4.42%) higher on 215,818 shares and a consolidation near this level would be a very healthy response to its recent monster moves.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.